During the second half of 2022,
In collaboration with veterinarians,
“The animal segment is a new market and a new source of revenue for us,” says
“Difficult-to-heal wounds that require prolonged treatments, increase the suffering for the animal, but also the costs for the animal owner. In the worst case, this can lead to amputation or having to put down the animal. ‘animal.”
Hard-to-heal wounds are a reality in animal health, as well as in human care. Injuries can be caused by everything from shards of glass and other sharp objects, to fights and bites and are also linked to diabetes. Healing can be made more difficult by bacteria and dirt from outside or by the animal licking the wound.
THIS IS CHLORASOLV
ChloraSolv is a debriding gel, based on unique hypochlorite technology, which is used with very good effect on leg ulcers and diabetic foot ulcers. The gel gently removes devitalized tissue and promotes the natural healing of wounds.1 ChloraSolv does not damage healthy tissue and is well tolerated by the patient.
- Eliasson B, Fagerdahl AM, Jönsson A, Apelqvist J. A single-arm, open-label, multicenter pilot investigation to assess the debriding effect of amino acid-buffered hypochlorite (ChloraSolv®) on chronic wounds covered with devitalized tissue during treatment six weeks.
Wound Care Diary (Accepted for publication).
TRADING VENUE AND CERTIFIED ADVISOR:
FOR MORE INFORMATION PLEASE CONTACT:
Email: [email protected]
Tel: +46 702 48 46 51
ON
The long-term vision of RLS is to be a leading research-driven platform in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize its market presence, RLS intends to work with partners to market its products globally. RLS is confident that the company’s technology platform and its unique features will help many patients around the world. Learn more at www.rls.global
https://news.cision.com/rls-global-ab/r/rls-global-introduces-chlorasolv-in-the-veterinary-care-segment-in-scandinavia,c3577470
(c) Decision 2022. All rights reserved., sources